We are live on ! Find out more
HRTX icon

Heron Therapeutics

180 hedge funds and large institutions have $1.69B invested in Heron Therapeutics in 2019 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 73 increasing their positions, 39 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 39

48% more call options, than puts

Call options by funds: $8.62M | Put options by funds: $5.82M

21% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 24

2% more funds holding

Funds holding: 176180 (+4)

3% less capital invested

Capital invested by funds: $1.74B → $1.69B (-$52.9M)

3.99% less ownership

Funds ownership: 118.54%114.55% (-4%)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
180
Holders Change
+4
Holders Change %
+2.27%
% of All Funds
3.95%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
29
Increased
73
Reduced
39
Closed
24
Calls
$8.62M
Puts
$5.82M
Net Calls
+$2.79M
Net Calls Change
+$2.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Allianz Asset Management
51
Allianz Asset Management
Germany
$2.58M -$566K -30,745 -18%
ARTA
52
A.R.T. Advisors
New York
$2.34M +$2.33M +126,478 New
State of New Jersey Common Pension Fund D
53
State of New Jersey Common Pension Fund D
New Jersey
$2.3M +$2.29M +124,200 New
AllianceBernstein
54
AllianceBernstein
Tennessee
$2.27M
Rafferty Asset Management
55
Rafferty Asset Management
New York
$2.19M -$1.61M -87,689 -43%
California State Teachers Retirement System (CalSTRS)
56
California State Teachers Retirement System (CalSTRS)
California
$2.13M +$25.3K +1,376 +1%
CPC
57
Congress Park Capital
New York
$2.06M +$29.4K +1,600 +1%
State of Wisconsin Investment Board
58
State of Wisconsin Investment Board
Wisconsin
$2.04M +$188K +10,200 +10%
Stifel Financial
59
Stifel Financial
Missouri
$2.04M +$15.8K +859 +0.8%
SI
60
Sofinnova Investments
California
$1.92M -$9.45M -513,583 -83%
RhumbLine Advisers
61
RhumbLine Advisers
Massachusetts
$1.86M +$20.7K +1,124 +1%
PAM
62
Private Asset Management
California
$1.86M +$85.6K +4,650 +5%
BC
63
Broadfin Capital
New York
$1.82M -$10.3M -559,761 -85%
PPA
64
Parametric Portfolio Associates
Washington
$1.8M +$722K +39,223 +68%
KCM
65
Kennedy Capital Management
Missouri
$1.78M -$50.3K -2,731 -3%
GC
66
Guggenheim Capital
Illinois
$1.75M -$268K -14,556 -13%
Ameriprise
67
Ameriprise
Minnesota
$1.75M +$109K +5,925 +7%
Barclays
68
Barclays
United Kingdom
$1.75M +$823K +44,722 +90%
UBS AM
69
UBS AM
Illinois
$1.65M +$429K +23,288 +35%
CM
70
Caption Management
Oklahoma
$1.46M +$987K +53,650 +215%
MSL
71
Mackay Shields LLC
New York
$1.42M +$33.1K +1,800 +2%
Fisher Asset Management
72
Fisher Asset Management
Washington
$1.39M
BA
73
Boston Advisors
Massachusetts
$1.37M +$447K +24,293 +49%
CS
74
Credit Suisse
Switzerland
$1.35M +$468K +25,433 +53%
RA
75
Royce & Associates
New York
$1.29M

HRTX Hedge Fund Activity: Q3 2019 in Review

180 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q3 2019, worth a combined $1.69B — down 3% from $1.74B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new HRTX positions and 24 closed out — a net gain of 5 holders — while 73 added to existing stakes and 39 trimmed.

The largest buyer was Franklin Resources, adding an estimated $18.6M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $26.7M sold.

  • 180 institutional investors held Heron Therapeutics (HRTX) as of Q3 2019, up from 176 in Q2 2019.
  • Funds reported $1.69B of Heron Therapeutics stock for Q3 2019, down 3% quarter-over-quarter.
  • 29 funds opened new Heron Therapeutics positions in Q3 2019 and 24 closed out, a net change of +5 holders.
  • The largest Heron Therapeutics buyer in Q3 2019 was Franklin Resources, an estimated $18.6M added.
  • The largest Heron Therapeutics seller in Q3 2019 was Eagle Asset Management, an estimated $26.7M sold.

Based on aggregated 13F filings for Q3 2019.